



# Digital Transformation in the Pharmaceutical Industry

Michael Pelosi


# GMP

10<sup>th</sup> PAN-RUSSIAN GMP CONFERENCE

# Astellas Mandatory Disclaimer



"The speaker is a paid employee of Astellas. This presentation is intended for informational purposes only and does not replace independent professional judgment. This presentation is not intended to provide medical or legal advice. Statements of fact, positions taken and opinions expressed are those of the speaker individually and, unless expressly stated to the contrary, do not necessarily reflect the opinion or position of the speaker's employer, Astellas, or any of its subsidiaries and/or related entities."



# Overview



- Introduction
- Inter-Company Quality Analytics (IMPALA) Consortium
- Revolutionizing Pharma Quality Assurance: Al Embedded Capabilities in QMS
- Al and the Quality Professional
- Challenges & Consideration
- Summary

# The Inter-Company Quality Analytics (IMPALA) Consortium













































#### Vision


By applying digital and advanced analytics methodologies at scale for biopharmaceutical quality, we bring life-changing medical solutions to patients faster.



#### Mission

We are transforming biopharmaceutical quality by codeveloping opensource tools. methodologies, and best practices to influence standards and by collaborating with biopharma industry leaders and health authorities to share knowledge and gain industrywide adoption of digital and advanced analytics methodologies to enhance quality activities.





# Al and the Quality Professional





- Quality
- GxPs
- Regulatory

Domain Expertise

Soft

Skills

Digital Leadershi p

- Data Storytelling
- Digital Fundamentals
- Data Analytics
- Experimentatio n



#### **Training Programs**

Bridge the knowledge gap



#### Hands-on Experience

Use practical applications of Al



- Communication
- Active Listening
- Collaboration
- Growth Mindset

Artificial Intelligence

- NLP, LBasics of Al (ML, LM, GenAl)
- Prompt Engineering
- Al workflows
- Emerging Regulations



#### Collaboration

 Encourage teamwork and share knowledge

# Challenges & Considerations



#### **Ethical Considerations**

Addressing bias and data privacy

### Regulatory Compliance

• Ensuring systems and processes meet regulations & standards

# Technical Challenges

Integration with legacy systems

# Summary



Health authorities are providing guidelines and regulations for the ethical use of AI in drug development and medical devices, emphasizing transparency and patient safety.

Building an effective AI use case involves identifying problems worth solving, scoping projects, and iterating on solutions to maximize value.

It is important for QA professionals to develop complimentary skills to adapt to the changing landscape brought about by AI technologies, ensuring they are equipped to handle these advancements.

As AI levels the field of knowledge accessibility, it will increase the importance of <u>humans-in-the-loop</u> and <u>critical thinking</u>.